Vaccines are Needed to Conclusively End HIV/AIDS and TB
Non-Commercial Satellite - MOSA04
Time: 08:00 – 10:00 Venue: Session Room 8
Organizer: Aeras, International AIDS Vaccine Initiative (IAVI)

This satellite will discuss the importance of vaccine development and deployment to conclusively end HIV/AIDS and TB; it will describe the progress already made, as well as the challenges faced, and the potential for enhanced collaboration between TB and HIV vaccine researchers and developers.

A Survival Guide for Advanced HIV Disease: Increasing Access to and Knowledge of Life-Saving Interventions
Non-Commercial Satellite – MOSA18
Time: 10:15 – 12:15 Venue: Session Room 13
Organizer: Center for Disease Control and Prevention

This session will provide healthcare providers, laboratorians, pharmacists, program planners and patients a better understanding of specific risks and the need for prompt and careful management to prevent or curb deadly opportunistic infections such as cryptococcal meningitis and tuberculosis and to successfully initiate ART in patients with advanced disease.

The HEAIDS Best Practice Model (Curriculum and Core Curriculum)
Non-Commercial Satellite – MOSA29
Time: 14:45 – 16:45 Venue: Session Room 6
Organizer: HEAIDS

This session will showcase a best practice model in South Africa that implements an HIV testing, counselling and screening, and social behaviour change programme called First Things First (HIV/STIS/TB).

HIV Mortality Trends in Africa in the Treatment Era: New Evidence from the ALPHA Network of Community-based HIV Surveillance Studies
Non-Commercial Satellite – MOSA45
Time: 17:00 – 19:00 Venue: Session Room 13
Organizer: The Network for Analyzing Longitudinal Population-based HIV/AIDS data on Africa (ALPHA), London School of Hygiene and Tropical Medicine

This session will use unique observational data from six countries of Eastern and Southern Africa, to provide direct information on age- and sex-specific mortality trends in HIV infected and uninfected adults, to describe the distribution of deaths on the treatment cascade, and how ART is changing causes of death amongst infected individuals.
Thinking Collectively on Integrated Healthcare in Communities: How to Address Co-morbidities while Building Resilient Health Systems and Improving the Lives of Individuals
Non-Commercial Satellite – TUSA05
Time: 07:00 – 08:30  Venue: Session Room 6
Organizer: The Lilly Foundation & Medtronic Foundation

This session will explore how to build integrated health systems which address broad needs, challenges and successes from those who have tried integrated care models, and how best to engage cadres of community health workers in the delivery of integrated care.

The Lancet Special Theme Issue: HIV, Viral Hepatitis, and TB among Prisoners
Symposia Session - TUSY07
Time: 14:30 - 16:00  Venue: Session Room 6
Co-Chairs: C Beyrer, USA and R Horton, UK

The lead authors of the Lancet Special Theme Issue will present: a global review of the burden of HIV, viral hepatitis and TB among prisoners; clinical care among incarcerated women and men; best practices for prevention in prisons and jails; human rights and the right to health care access; and two region-specific presentations—on prisoners in Eastern Europe and Central Asia and Sub-Saharan Africa.

Effective Integrated Clinical and Programmatic Service Delivery for People Living with HIV who use Alcohol and Drugs
Scientific workshop – TUWS09
Time: 14:30 - 17:00  Venue: Session Room 8
Level: Intermediate

The goal of this workshop is to increase quality and access of treatment programming for people living with HIV who use drugs and alcohol. It will share experiences and lessons learned across different regions focused on improving health among these vulnerable populations, addressing comorbidities such as hepatitis C and tuberculosis.

Synergistic Epidemics: New Drugs, New Challenges
Symposia Session – TUSY11
Time: 16:30 - 18:00  Venue: Session Room 12
Co-Chairs: F Altice, US and M Klein, Canada

This session focuses on the pragmatic issues raised by the development of newer treatments for HIV, HCV, and TB. It provides an overview and a critical analysis of current drug pipelines, the cost implications in resource-limited settings, drug interactions (including medications used to treat other comorbidities), issues of access for key populations, and innovative methods to increase access and epidemic control.

Stigma and Discrimination: From Research to Action
Non-Commercial Satellite – TUSA13
Time: 18:30 – 20:30  Venue: Session Room 1
Organizer: South African National AIDS Council

Results from South Africa’s first TB and HIV stigma index survey will be presented, along with an outline of South Africa’s multi-sectoral response to deliver practical and innovative actions to counter stigma and discrimination.

Financing South Africa’s HIV Response
Non-Commercial Satellite – TUSA24
Time: 18:30 – 20:30  Venue: Session Room 12
Organizer: UNAIDS, National Department of Health and Results for Development Institute

During this session, the successes of South Africa’s HIV programme and approaches to sustainably financing the epidemic response will be showcased.
What is our goal?
Plenary Session – WEPL01
Time: 08:45 – 10:55  Venue: Session Room 1
Co-Chairs: A Motsoaledi, South Africa and J Philpott, Canada

09:20  TB and Co-Infections: The Long Game, A Pozniak, UK
WEPL0103

Taking TB from Testing to Treatment
Oral Abstract Session Track B – WEAB02
Time: 14:30 – 16:00  Venue: Session Room 1
Co-Chairs: S Hader, USA and T Gaolathe, Botswana

14:30  WEAB0201  Daily is better than thrice-weekly anti-tuberculosis therapy in HIV patients with culture
confirmed pulmonary TB: a randomised controlled clinical trial from south India
G Narendran, India

14:45  WEAB0202  Intensified tuberculosis case-finding among people living with HIV: diagnostic yield of
Xpert MTB/RIF, urine lipoarabinomannan and liquid culture. F Collins, Uganda

15:00  WEAB0203  Cytomegalovirus viraemia and 12-week mortality among hospitalised adults with HIV-
associated tuberculosis in Khayelitsha Hospital, South Africa: a prospective cohort study. A Ward, South Africa

15:15  WEAB0204  Yield of community health worker-driven intensified case finding for tuberculosis
among HIV-positive patients in rural Malawi. K Simon, Malawi

15:30  WEAB0205LB  High-dose rifampicin tuberculosis treatment regimen to reduce 12-month mortality of
TB/HIV co-infected patients: the RAFA trial results. C S Merle, WHO, Switzerland

Developing the Next South African National Strategic Plan for HIV, TB
and STIS
Non-Commercial Satellite – WESA13
Time: 18:30 – 20:30  Venue: Session Room 1
Organizer: South African National AIDS Council

For the next five years the South African NSP will set the stage for the country to
attain the goals of the 2030 National Development Plan: an AIDS free generation
and a concomitant reduction in TB deaths and TB cases. Views on the successes,
“game-changers” that need to be scaled up and innovations that could be tested
for attaining these ambitious goals will be shared during this satellite.

Towards a Joint Response to HIV in Prisons in Africa
Non-Commercial Satellite - WESA14
Time: 18:30 - 20:30  Venue: Session Room 2
Organizer: UNODC, African HIV in Prisons Partnership Network

UNODC will launch a publication containing assessments of HIV, STIs, TB and
health needs in prisons in Southern and Eastern Africa and share guidelines and
operating procedures, as well as examples of good practice on health and HIV
service provision in prison settings in Sub-Saharan Africa.

THURSDAY, 21 JULY 2016

Diagnosis and Treatment of TB in People Living with HIV: Results of TB
Fast Track, XPHACTER, and Lesedi Kamoso
Non-Commercial Satellite – THSA07
Time: 07:00 – 08:30  Venue: Session Room 8
Organizer: London School of Hygiene & Tropical Medicine and The Aurum Institute

In this session findings from three South African studies designed to inform
strategies to reduce morbidity and mortality due to TB will be discussed, together
with their implications for current practice with respect to TB investigation and
management among HIV-positive people.

Produced by the Global TB Programme, World Health Organization,
20 Avenue Appia, CH-1211 Switzerland Website: www.who.int/tb/areas-of-work/tb-hiv/en/
What are the key barriers
Plenary Session – THPL01
Time: 08:45 – 10:45 Venue: Session Room 1
Co-Chairs: L Hjelmåker, Sweden and S Abdool Karim, South Africa
08:45 Award presentation: IAS TB/HIV Research Prize
THPL0101

Maximizing Survival from Tuberculosis in Late Presenters: the Answer Lies in the Algorithm!
Scientific Workshop – THWS03
Time: 11:00 – 12:30 Venue: Session Room 10
Facilitators: A Baddeley, WHO, Switzerland and D Kibuga, WHO, Republic of Congo

This workshop will review evidence around the need for expedited diagnosis and treatment of HIV-associated TB, share new algorithms to diagnose and manage HIV-associated TB. It will also give a chance for participants to exchange their experience in the roll-out of strategies to reduce mortality from HIV-associated TB.

11:05 Review of the evidence on mortality from HIV-associated TB and blocks in the cascade of care through from early case detection to timely treatment. N Ford, WHO Switzerland
11:25 Overview of the new algorithm to expedite diagnosis, to include elements such as the use of rapid diagnostics, LF-LAM and presumptive TB treatment Y Hamada, WHO, Switzerland
11:45 Addressing the challenges in the successes of expediting TB treatment among PLHIV who are seriously ill: experience from Kenya, C Olwande, Kenya

Optimizing Laboratory Diagnostics
Oral Poster Discussion Session Track B – THPDB02
Time: 13:00 – 14:00 Venue: Session Room 13
Co-Chairs: C Kityo, Uganda and T Peter, Botswana

13:05 Utility of GeneXpert MTB/RIF assay in the diagnosis of extrapulmonary tuberculosis P Ramjathan, South Africa

Connecting the Dots: Toward Seamless Service Integration
Oral Abstract Session Track E – THAE02
Time: 14:30 – 16:00 Venue: Session Room 2
Co-Chairs: T Mastro, USA and E Charlebois, USA

15:20 One-stop shopping for TB and HIV services improved initiation of antiretroviral therapy for patients who are co-infected in eastern Uganda. A Mukuye, Uganda

Strengthening Health Care Systems by Supporting and Expanding the Roles of Nurses: Strategies to Improve Access and Outcomes
Leadership Workshop – THWS08
Time: 14:30 – 17:00 Venue: Session Room 7

This workshop examines specific skills-building techniques and strategies for innovative nurse-led programming to build capacity in low-income countries. The session covers educational support, workplace benefits and challenges perceived by nurses regarding healthcare task-shifting, including expanding access for patients co-infected with MDR-TB/HIV in South Africa.

Bang for the Buck: Cost-Effectiveness and Modelling
Oral Abstract Session Track E – THAE03
Time: 16:30 – 18:00 Venue: Session Room 2

16:45 Anticipated reductions in long-term tuberculosis incidence and associated cost savings with adoption of the Treat All People Living with HIV policy in Botswana, 2016-2035. B. Kgwaadira, Botswana
Making 90-90-90 a reality: business unusual in South Africa
Non-commercial satellite – THSA20
Time: 18:30 - 20:30 Venue: Session Room 8
Organizer: National Department of Health South Africa and UNAIDS

High-level officials including representatives from the South African Government and PEPFAR will describe the innovative bottom-up District Implementation Planning process which was used to identify bottlenecks of poor performance which, in turn, informed the development of South Africa's plans to achieve 90-90-90 targets for HIV and TB by 2020. Speakers will also reflect on lessons learned and suggest future directions.

Sex in the City of Gauteng - The Uncomfortable Truth
Non-Commercial Satellite – THSA23
Time: 18:30 - 20:30 Venue: Session Room 11
Organizer: Gauteng AIDS Council

The Gauteng response to HIV and TB is a collaboration between stakeholders in government, sectors of civil society, organized labour unions, and business. This session will highlight the strengths and challenges of a multi-sector response in a highly urbanized setting with complex migrant populations.

FRIDAY, 22 JULY 2016

Getting the money we need: the case for investment and using resources for maximum impact
Symposia Session – FRSY01
Time: 11:00 - 12:30 Venue: Session Room 2
Chair: D Wilson, USA
This session will provide key arguments to make the case for increased investment in the response to AIDS, discuss issues for improving the use of funding, and outline priorities for advocacy on resource mobilization. The session will also discuss the use of innovative finance approaches and makes the case for joint HIV/TB investments.

AIDS 2016 Pre-Conference Report Back
Special Session - FRSS02
Time: 13:00-14:00 Venue: Session Room 7
Chair: K Osborne, Switzerland

Rapporteurs will present highlights from the official AIDS 2016 pre-conferences, including TB2016, Action + Access, UN 90-90-90 Target Workshop, Living 2016 and the 3rd HIV/Viral Hepatitis Co-infection Meeting.

TB/HIV Networking Zone (sessions throughout the conference)
Venue: Stall 610 Global Village GV1
Organizer: TB/HIV Care Association

This dedicated TB-HIV networking Zone aims to increase participant knowledge of the dual TB-HIV epidemic, bridge the gap between HIV and TB communities and organizations and identify opportunities for communities, key affected populations, researchers, donors, and policy makers to collaborate on TB-HIV research, policy, and programme design. For details of the TB/HIV networking zone programme please visit the link below: